Sei Investments Co. lifted its holdings in Achaogen, Inc. (NASDAQ:AKAO) by 22.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,000 shares of the biopharmaceutical company’s stock after buying an additional 16,000 shares during the quarter. Sei Investments Co. owned 0.21% of Achaogen worth $1,404,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the stock. Legal & General Group Plc purchased a new stake in Achaogen during the second quarter worth $168,000. Sigma Planning Corp boosted its position in Achaogen by 9.6% during the second quarter. Sigma Planning Corp now owns 9,450 shares of the biopharmaceutical company’s stock worth $205,000 after purchasing an additional 825 shares in the last quarter. Bank of Montreal Can boosted its position in Achaogen by 33.3% during the second quarter. Bank of Montreal Can now owns 10,000 shares of the biopharmaceutical company’s stock worth $217,000 after purchasing an additional 2,500 shares in the last quarter. Ardsley Advisory Partners purchased a new stake in Achaogen during the second quarter worth $217,000. Finally, JPMorgan Chase & Co. boosted its position in Achaogen by 691.2% during the second quarter. JPMorgan Chase & Co. now owns 11,077 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 9,677 shares in the last quarter. Hedge funds and other institutional investors own 85.81% of the company’s stock.
A number of research firms have commented on AKAO. Mizuho reiterated a “buy” rating and set a $28.00 target price on shares of Achaogen in a research report on Thursday, November 30th. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Achaogen in a research report on Thursday, November 9th. Zacks Investment Research downgraded Achaogen from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Stifel Nicolaus decreased their target price on Achaogen from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, November 9th. Finally, BidaskClub downgraded Achaogen from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. Achaogen currently has an average rating of “Buy” and an average price target of $25.78.
Achaogen, Inc. (NASDAQ:AKAO) opened at $10.47 on Thursday. Achaogen, Inc. has a 1-year low of $4.82 and a 1-year high of $27.79. The company has a current ratio of 6.99, a quick ratio of 6.99 and a debt-to-equity ratio of 0.08.
Achaogen (NASDAQ:AKAO) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.13). Achaogen had a negative return on equity of 80.44% and a negative net margin of 593.61%. The company had revenue of $0.58 million during the quarter, compared to analyst estimates of $2.09 million. During the same period last year, the firm earned ($0.41) earnings per share. The business’s revenue was down 96.4% compared to the same quarter last year. equities analysts anticipate that Achaogen, Inc. will post -3.06 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3078824/sei-investments-co-has-1-40-million-position-in-achaogen-inc-akao.html.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.